Your global partner for serological diagnostic products (autoimmune diseases, infectious serology and allergology) made
in Germany For the optimal treatment of diabetes mellitus, it is essential to differentiate type I diabetes mellitus (TIDM) and latent autoimmune diabetes in adults (LADA) from type II diabetes mellitus. The investigation of autoantibodies −
found only in TIDM and LADA − contributes greatly to diagnosis and also aids in the prognosis.

EUROIMMUN AG offers a broad panel of state-of-the-art test systems for diabetes autoantibody diagnostics.
Autoantibodies in TIDM or LADA are directed against the insulin-producing islet cells of the pancreas. The main target antigens of these islet cell antibodies (ICA) are:
• Glutamic acid decarboxylase (GAD)
• Tyrosine phosphatase (IA2)
• Insulin
The standard method for determining ICAs is the indirect immunofluorescence test (IIFT) with primate pancreas as
the antigenic substrate.

Specialized microplate ELISAs provide the monospecific detection of antibodies against GAD or IA2, or the bispecific
detection of both antibodies in one reagent well. The ELISAs can be fully automated, allowing large sample series
to be processed quickly and efficiently. Anti-insulin antibodies are determined most effectively via radioimmunoassay
(RIA). EUROIMMUN’s product portfolio includes RIAs for the detection of anti-insulin, anti-GAD and anti-IA2 bodies. EUROIMMUN’s annual participation in the Diabetes Autoantibody Standardization Program demonstrates that our assays are among the best performing on the market and can be relied upon to provide excellent results.